Terms ending in 2037
Every in-force patent on Astellas US LLC's record whose computed term ends in 2037, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,874,641 | Methods of Treating Acute Kidney Injury In force · High confidence | Astellas Engineered Small Molecules US, Incorporated | In force | High confidence | |
| US 11,034,670 | Poly-Adp Ribose Polymerase (PARP) Inhibitors In force · High confidence | Astellas Engineered Small Molecules US, Incorporated | In force | High confidence |
2 of 2 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.